List of Excipients in Branded Drug ARTISS

« Back to Dashboard

ARTISS Excipient Strategy and Commercial Opportunities

Last updated: October 17, 2026

ARTISS is a specialized human fibrin sealant for securing autologous skin grafts to surgically prepared burn wounds. Its commercial differentiation depends less on novel excipients than on controlled clotting kinetics, plasma-derived protein quality, cold-chain performance, applicator design, and procedure-specific evidence. The principal opportunities are improved delivery systems, longer refrigerated shelf life, reduced handling complexity, and next-generation fibrin-sealant formulations that reduce dependence on human plasma proteins.

What is ARTISS and how does its formulation work?

ARTISS is a two-component fibrin sealant manufactured by Baxter Healthcare Corporation. The product contains a sealer protein solution with human fibrinogen and a thrombin solution with human thrombin. When mixed at the wound site, fibrinogen is converted into fibrin, creating an adhesive matrix that secures the skin graft.

The product is designed for adhesion rather than rapid hemostasis. ARTISS uses a low thrombin concentration and has a relatively slow setting profile compared with faster-acting fibrin sealants. The FDA label identifies ARTISS for adhesion of autologous skin grafts to surgically prepared wound beds resulting from burns in adults and pediatric patients aged one year and older.[1]

Product attribute	ARTISS
Active biological components	Human fibrinogen and human thrombin
Primary use	Adherence of autologous skin grafts
Main clinical setting	Burn surgery and reconstructive procedures
Dosage form	Frozen, two-component fibrin sealant
Administration	Spray or drip application using dedicated delivery systems
Regulatory category	Biologic product licensed under a biologics license application
Key differentiation	Slow-setting adhesive profile for graft fixation
Principal commercial constraint	Plasma-derived manufacturing and frozen logistics

ARTISS is not a conventional small-molecule drug. Generic substitution under an abbreviated new drug application is not the expected competitive pathway. Competition is more likely to arise from other fibrin sealants, surgical adhesives, autologous tissue technologies, and biosimilar-like or interchangeable biologic development strategies.

What excipients are used in ARTISS?

ARTISS uses excipients to stabilize plasma-derived proteins, control ionic conditions, support thrombin activity, and maintain product performance during freezing and thawing.

Sealer protein solution

The sealer protein solution contains human fibrinogen and supporting excipients that include:

• Human albumin
• L-arginine hydrochloride
• Sodium chloride
• Sodium citrate dihydrate
• Polysorbate 80
• Synthetic aprotinin
• Water for injection

The sealer protein solution is the more compositionally complex component because fibrinogen is vulnerable to aggregation, denaturation, and loss of functional activity during processing and storage. Albumin provides a stabilizing protein matrix. Arginine can reduce nonspecific protein aggregation. Citrate and sodium chloride control ionic conditions. Polysorbate 80 limits surface-induced aggregation and protein adsorption to containers and delivery components. Synthetic aprotinin helps inhibit premature proteolysis of fibrinogen.

Thrombin solution

The thrombin solution contains:

• Human thrombin
• Human albumin
• Sodium chloride
• Calcium chloride dihydrate
• Water for injection

Calcium chloride is functionally important because calcium ions support thrombin-mediated conversion of fibrinogen to fibrin. Albumin and sodium chloride support protein stability and isotonicity.

The ARTISS label reports quantitative ranges for the principal protein and excipient components rather than treating the formulation as a simple fixed-dose chemical composition.[1] That approach reflects the biological variability inherent in plasma-derived proteins.

Why are ARTISS excipients commercially important?

The excipients are commercially important because they affect four value drivers:

1. Protein stability during frozen storage.
2. Thawing time and handling requirements.
3. Fibrin formation and adhesion performance.
4. Manufacturing yield and lot-to-lot consistency.

The commercial objective is not simply to identify a replacement for one excipient. A change to albumin, arginine, citrate, surfactant, or calcium concentration can affect fibrinogen recovery, viscosity, clot structure, sprayability, immunogenicity risk, and comparability.

Human albumin

Human albumin is a critical stabilizer but adds supply, cost, and plasma-derivative qualification requirements. Albumin sourcing requires donor-screening controls, viral safety controls, and supply continuity planning. A formulation that uses less albumin, a more concentrated albumin grade, or a recombinant stabilizer could reduce exposure to plasma supply constraints.

A replacement would face a high comparability burden. Albumin may interact with fibrinogen, thrombin, container surfaces, and the delivery device. A substitute must preserve potency after freeze-thaw cycling and demonstrate acceptable particle, aggregate, and degradation profiles.

L-arginine hydrochloride

Arginine is a common protein-stabilizing excipient. Its commercial value lies in reducing aggregation without requiring a major change to the biological actives. A developer could evaluate alternative amino acids or stabilizer systems, but such changes may alter viscosity and protein solubility.

Arginine concentration also affects the formulation's osmolarity and local tissue exposure. Any change would require assessment of wound tolerability, spray performance, and fibrin architecture.

Polysorbate 80

Polysorbate 80 reduces adsorption and aggregation at air-liquid and container interfaces. It is also a known source of degradation concerns, including peroxide formation and hydrolytic breakdown. These degradation products can affect protein quality and particulate formation.

Commercial opportunities include:

• Lower-polysorbate formulations.
• More oxidation-resistant surfactant systems.
• Alternative nonionic surfactants.
• Container and syringe surfaces that reduce the need for surfactant.

A surfactant change could support longer shelf life or reduce visible and subvisible particle risk. It would also trigger extractables, leachables, compatibility, and process-validation work.

Citrate and calcium chloride

Citrate and calcium chloride provide control over coagulation conditions. Their concentrations influence the rate and structure of fibrin formation. A lower thrombin concentration combined with tightly controlled calcium availability enables the slower setting behavior associated with ARTISS.

This creates a formulation opportunity for procedure-specific products:

• Slower setting for large-area skin graft fixation.
• Faster setting for smaller grafts or high-mobility anatomical sites.
• Adjustable thrombin concentrations for different surgical workflows.
• Dual-chamber systems that alter the mixing ratio at the point of use.

Such changes would likely produce a new product or supplement rather than a simple line extension.

What formulations are protected by ARTISS?

ARTISS is protected commercially by a combination of formulation know-how, manufacturing controls, biological source material, delivery systems, regulatory data, and brand recognition. The public FDA prescribing information does not identify specific active patent numbers or patent expiration dates for the product.[1]

ARTISS is not expected to have a conventional Orange Book patent listing because it is a biologic rather than a small-molecule drug approved through an NDA. The relevant regulatory framework is the Public Health Service Act and the biologics license pathway. A competitor would need to evaluate the BLA, Purple Book relevance, biologic comparability requirements, manufacturing controls, and any separately claimed device or process intellectual property.

Likely protectable technical areas

The potentially valuable IP categories include:

• Fibrinogen and thrombin purification methods.
• Viral inactivation and pathogen-reduction processes.
• Stabilization of plasma-derived proteins.
• Freeze-thaw cycle control.
• Two-component mixing systems.
• Spray applicator geometry.
• Cannula and nozzle design.
• Delivery methods for skin graft fixation.
• Low-thrombin adhesive formulations.
• Combination use with meshed or full-thickness grafts.

Formulation claims covering the exact ARTISS excipient system may have limited remaining commercial life depending on filing dates and claim scope. Manufacturing and device claims can remain relevant even after composition claims expire because they may be difficult to design around without reducing product performance.

When does ARTISS lose exclusivity?

ARTISS does not have a single small-molecule patent-expiration date that determines generic entry. Commercial exclusivity is divided among biologic exclusivity, patents, manufacturing know-how, clinical data, and regulatory complexity.

The FDA approved ARTISS in 2008 for skin-graft adhesion in burn patients.[1] The statutory 12-year reference-product exclusivity period for a biologic approved under the modern BPCIA framework would not provide a current barrier for a product approved in 2008. No current Orange Book exclusivity period applies.

The principal remaining barriers are therefore:

• Demonstration of comparable biological activity.
• Plasma-derived raw-material sourcing.
• Viral safety and impurity control.
• Product-specific clinical evidence.
• Delivery-device compatibility.
• Hospital adoption and surgeon familiarity.
• Cold-chain and inventory management.

A competitor would not ordinarily launch an ARTISS equivalent as a traditional generic. The most credible pathways would involve a new biologic, a biosimilar-style development program where legally and technically applicable, or a distinct fibrin-sealant product supported by its own clinical and manufacturing package.

How does ARTISS compare with competing fibrin sealants?

ARTISS occupies a narrower commercial position than products designed primarily for hemostasis.

Product	Manufacturer or marketer	Main positioning	Setting profile	Commercial distinction
ARTISS	Baxter	Skin-graft adhesion	Slower	Designed for graft fixation
TISSEEL	Baxter	Hemostasis and tissue sealing	Faster than ARTISS	Broader surgical use
EVICEL	Johnson & Johnson subsidiary/Omrix	Hemostasis	Thrombin-based	Plasma-derived fibrin sealant
VISTASEAL	Johnson & Johnson subsidiary/Ethicon	Hemostasis	Rapid seal formation	Surgical hemostasis focus
Synthetic tissue adhesives	Multiple companies	Closure or adhesion	Product-specific	May avoid plasma-derived inputs

ARTISS has a clear niche in burn reconstruction and plastic surgery. Its narrower indication limits the addressable market but supports procedure-specific pricing and clinical positioning. TISSEEL and other hemostatic sealants compete for broader operating-room use, while ARTISS competes on graft adherence, handling time, and tissue integration.

What commercial opportunities exist for ARTISS excipients and delivery systems?

Room-temperature or shorter thawing formats

ARTISS is distributed as a frozen product, which creates inventory and procedural burdens. A stable refrigerated or room-temperature format would have substantial value if it preserved fibrinogen potency, thrombin activity, and sterility.

Potential technologies include:

• Lyophilized fibrinogen and thrombin components.
• Dual-chamber cartridges with separate reconstitution.
• Refrigerated liquid formulations.
• Improved cryoprotectant systems.
• Ready-to-use applicators with controlled thawing.

The principal development risk is maintaining protein activity without changing clot kinetics.

Reduced plasma dependence

A lower-plasma formulation could reduce supply risk and simplify viral-safety management. Opportunities include:

• Recombinant thrombin.
• Recombinant fibrinogen.
• Recombinant albumin.
• Synthetic or recombinant protease inhibitors.
• Reduced reliance on human albumin as a stabilizer.

Replacing both biological actives would create a substantially different product. Replacing only thrombin may be more technically manageable, but the product would still require extensive comparability and clinical evaluation.

Improved sprayability

Large-area burn wounds require consistent coverage. Commercial value can come from better control over:

• Droplet size.
• Spray width.
• Component mixing.
• Nozzle clogging.
• Required gas pressure.
• Application distance.
• Delivered volume per square centimeter.

A delivery-system improvement may be easier to commercialize than a new excipient because it can preserve the established formulation while improving operating-room workflow. Device patents and human-factors data may provide meaningful competitive protection.

Procedure-specific presentations

Potential line extensions include:

• Small-volume kits for limited grafts.
• Large-volume kits for extensive burn wounds.
• Applicators optimized for meshed grafts.
• Low-volume precision applicators for facial or hand reconstruction.
• Integrated systems compatible with robotic or minimally invasive surgery.

These products could expand utilization without requiring a new active biological mechanism.

What regulatory and manufacturing barriers affect commercial entry?

ARTISS manufacturing is difficult to replicate because the product depends on plasma-derived proteins and tightly controlled biological processes. The major barriers include:

• Donor qualification and plasma-pool management.
• Viral inactivation and removal.
• Fibrinogen and thrombin purification.
• Control of proteolytic impurities.
• Aggregate and particle control.
• Freeze-thaw stability.
• Sterile filling of protein formulations.
• Mixing-device validation.
• Spray-device compatibility.
• Clinical demonstration of graft adherence.

A formulation change involving an excipient can affect product quality, safety, and efficacy simultaneously. FDA review would likely focus on comparability, potency assays, impurities, immunogenicity, local tolerability, and performance under actual surgical conditions.

The highest-value manufacturing improvements are those that reduce batch failure, increase protein recovery, shorten thawing time, and lower dependence on constrained plasma inputs.

What patent litigation and Paragraph IV risks affect ARTISS?

Paragraph IV litigation is not the principal risk model for ARTISS because the product is not an NDA-based small molecule with standard Orange Book-listed patents. A competitor would be more likely to face biologic regulatory barriers, patent disputes over manufacturing or delivery technology, and freedom-to-operate issues involving fibrin-sealant formulations.

Potential litigation targets include:

• Recombinant or plasma-derived fibrinogen production.
• Thrombin purification.
• Viral inactivation.
• Stabilizer combinations.
• Freeze-dried fibrin sealants.
• Dual-syringe mixing systems.
• Spray applicators.
• Skin-graft fixation methods.

Settlement agreements involving ARTISS-specific generic entry are not a central feature of the public regulatory record cited here. Competitive entry is more likely to be shaped by development economics and technical comparability than by a conventional Paragraph IV settlement.

How strong is the ARTISS patent estate?

The ARTISS commercial moat is stronger in manufacturing and product integration than in basic excipient selection. Human fibrinogen, thrombin, albumin, arginine, citrate, calcium chloride, and polysorbate 80 are established pharmaceutical ingredients. Broad claims to those ingredients would provide limited defensibility.

The strongest potential protection is likely to come from:

1. Product-specific combinations with defined biological activity.
2. Low-thrombin graft-adhesion formulations.
3. Controlled delivery systems.
4. Manufacturing processes that achieve consistent fibrinogen quality.
5. Use claims tied to burn-graft fixation.
6. Device and formulation compatibility.

The weakest protection would likely be an isolated claim to a conventional stabilizer such as albumin or arginine without a narrow performance limitation.

What generic launch scenarios exist for ARTISS?

Three entry scenarios are commercially plausible.

Scenario 1: Direct biologic competitor

A competitor develops a plasma-derived fibrin sealant with a similar indication and delivery system. This route has the highest clinical and manufacturing burden but could compete directly on price and supply.

Scenario 2: Improved formulation

A competitor launches a product with faster thawing, refrigerated storage, longer shelf life, or reduced plasma dependence. Differentiation would come from logistics and operating-room efficiency rather than exact compositional similarity.

Scenario 3: Adjacent surgical adhesive

A synthetic or recombinant adhesive targets the same graft-fixation procedure without replicating ARTISS's formulation. Such a product could avoid some plasma-related constraints but would need to demonstrate adequate adhesion, biocompatibility, wound healing, and ease of use.

Key Takeaways

• ARTISS is a plasma-derived fibrin sealant for autologous skin-graft adhesion in burn surgery.
• Its formulation uses human albumin, arginine, citrate, sodium chloride, polysorbate 80, synthetic aprotinin, and calcium chloride to stabilize proteins and control fibrin formation.
• The commercial value of the excipients lies in stability, thawing performance, sprayability, and manufacturing consistency.
• ARTISS is not a conventional small-molecule product and does not follow the standard Orange Book or Paragraph IV generic-entry model.
• The most attractive opportunities are improved delivery devices, reduced thawing time, refrigerated or room-temperature formats, and lower-plasma formulations.
• Recombinant fibrinogen, recombinant thrombin, and recombinant albumin could reduce supply risk but would require substantial regulatory and clinical development.
• The strongest competitive protection is likely to reside in manufacturing know-how, delivery systems, formulation performance, and procedure-specific evidence.
• A direct competitor would face significant barriers from plasma sourcing, viral safety, biological comparability, and surgical-device validation.

FAQs

Is ARTISS a biologic or a generic drug?

ARTISS is a biologic fibrin sealant containing human fibrinogen and human thrombin. It is not a conventional small-molecule generic drug.

Does ARTISS contain bovine aprotinin?

The ARTISS formulation identifies synthetic aprotinin in the sealer protein solution. This distinguishes it from products that use animal-derived aprotinin.

Can polysorbate 80 be removed from ARTISS?

Polysorbate 80 could theoretically be reduced or replaced, but any change would require evaluation of protein aggregation, particles, stability, container compatibility, and fibrin-sealant performance.

What is the most valuable ARTISS product improvement?

A validated ready-to-use or substantially faster-thawing presentation would likely offer the clearest commercial value because it could reduce operating-room delays and cold-chain handling while preserving the existing clinical use.

Are biosimilars likely to replace ARTISS?

A biosimilar-style competitor is possible, but the practical barriers are high. A differentiated fibrin sealant with improved logistics or a recombinant component may be more commercially attractive than an exact ARTISS copy.

References

1. U.S. Food and Drug Administration. (2024). ARTISS fibrin sealant human: Prescribing information. Baxter Healthcare Corporation.

2. U.S. Food and Drug Administration. (2023). Approved cellular and gene therapy products. Center for Biologics Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Questions and answers on biosimilar development and the BPCI Act. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2022). Guidance for industry: Immunogenicity assessment for therapeutic protein products. Center for Drug Evaluation and Research.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.